Document Detail


Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules.
MedLine Citation:
PMID:  11295089     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We retrospectively reviewed the medical records of 97 children (59 boys and 38 girls) with a median age of 13 +/- 4 years who had been treated with continuous infusion of doxorubicin at a dosage of 60 mg/m2 over 24 h (61 patients) or at a dosage of 75 mg/m2 over 72 h (36 patients). The drug was administered every 3 weeks. The cardiac status of patients was evaluated as a baseline and every 6 months during, and following therapy (median, 30.5 months). The evaluations included M-mode and two-dimensional echocardiography. Congestive heart failure developed in only one patient in this series, an 8-year-old girl who ultimately died of her cardiac complication. This incidence of doxorubicin-induced cardiotoxicity was compared with that seen in a control group of pediatric patients previously treated with doxorubicin at similar dosages but with a rapid infusion. The result compared favorably to the 13% incidence of cardiotoxicity (p = 0.03) and 7% mortality (p < 0.01) in the control group. No changes in the levels of tumor response were noted in children treated by continuous infusion when compared with historical controls. Continuous-infusion schedules of doxorubicin thus result in fewer incidences of cardiotoxicity in children and should be considered for wider application in pediatric cancer patients receiving doxorubicin.
Authors:
S G Berrak; M S Ewer; N Jaffe; P Pearson; H Ried; H A Zietz; R S Benjamin
Related Documents :
7588929 - The value of dipyridamole echocardiography in risk stratification before vascular surge...
22445239 - Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive...
15309469 - Does down syndrome affect the outcome of congenital duodenal obstruction?
23669129 - Medical outcomes associated with nonmedical use of methadone and buprenorphine.
11193269 - High survival in adult patients with acute respiratory distress syndrome treated by ext...
11251269 - Is there a role for extracorporeal life support after stage i norwood?
23199859 - Immediate weight bearing after modified percutaneous achilles tendon repair.
18846799 - Percutaneous vertebroplasty in osteoporotic vertebral compression fractures: our initia...
21182509 - Full-spectrum light phototherapy for atopic dermatitis.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Oncology reports     Volume:  8     ISSN:  1021-335X     ISO Abbreviation:  Oncol. Rep.     Publication Date:    2001 May-Jun
Date Detail:
Created Date:  2001-04-11     Completed Date:  2001-07-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9422756     Medline TA:  Oncol Rep     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  611-4     Citation Subset:  IM    
Affiliation:
Departments of Medical Specialties and Melanoma/Sarcoma and the Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Antineoplastic Agents / administration & dosage,  adverse effects*
Child
Child, Preschool
Doxorubicin / administration & dosage,  adverse effects*
Drug Administration Schedule
Electrocardiography
Female
Heart / drug effects*
Heart Failure / chemically induced,  epidemiology*,  prevention & control
Humans
Incidence
Infant
Infusions, Intravenous
Male
Neoplasms / drug therapy
Retrospective Studies
Risk Factors
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacokinetics of intraoperative intrapleural cisplatin chemotherapy of various osmolarities in ca...
Next Document:  Mitochondrial genotypes and radiation-induced micronucleus formation in human osteosarcoma cells in ...